A

    Apogee Therapeutics, Inc. Common Stock (APGE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $135.08
    +0.11 (+0.08%)

    Market Cap: $10.22B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    38%(5/13)
    Avg Surprise
    -20.82%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-1.20
    Range$-1.27 - $-1.13
    9 analysts
    EPS Revisions
    1
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$-1.18+1.8%
    60d ago$-1.16+3.2%
    30d ago$-1.16+3.5%
    7d ago$-1.16+3.5%
    Current$-1.20
    Revenue Consensus
    $0
    Range$0 - $0
    10 analysts
    Dec 31, 2026
    EPS Consensus$-1.46
    Range$-1.82 - $-1.18
    7 analysts
    Revenue Consensus
    $-10000000
    Range$-10000000 - $-10000000
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.46---
    Sep 26EST
    		-$-1.20---
    Jun 26
    		$-1.14$-1.10-3.64%Miss-0.9%
    Mar 26
    		$-1.06$-1.13+6.19%Beat-11.6%
    Dec 25
    		$-1.03$-0.62-66.13%Miss+12.7%
    Sep 25
    		$-1.11$-1.15+3.48%Beat-29.1%
    Jun 25
    		$-1.13$-1.05-7.62%Miss-88.3%
    Mar 25
    		$-0.95$-1.19+20.17%Beat-48.4%
    Dec 24
    		$-1.18$-0.62-90.32%Miss-268.7%
    Sep 24
    		$-0.86$-0.74-16.22%Miss-68.6%
    Jun 24
    		$-0.60$-0.55-9.09%Miss+84.1%
    Mar 24
    		$-0.64$-0.65+1.54%Beat+73.1%
    Dec 23
    		$-0.32$-0.49+34.69%Beat-
    Sep 23
    		$-0.51$-0.42-21.43%Miss-
    Jun 23
    		$-3.78$-1.70-122.35%Miss-
    Mar 23
    		$-2.38$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-31.12EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-32.50%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio26.44xQuick Ratio26.44x
    Trading Statistics
    Beta0.34Avg Volume1.26M
    52-Week High$134.9952-Week Low$35.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$134.84
    SMA 20$134.68
    SMA 50$134.04
    SMA 200$91.25
    EMA 10$134.86
    EMA 20$134.35
    EMA 50$127.46
    EMA 200$95.57

    MACD

    Line: 1.27Signal: 1.72Hist: -0.45

    ADX

    ADX: 65.1+DI: 45.5-DI: 8.7

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down20.0
    PSAR$134.49

    Bollinger Bands

    Upper Band$135.15
    Lower Band$134.21
    %B Position70%(Middle)
    Band Width0.92

    RSI (14-Day)

    Overbought
    79.0

    Momentum Oscillators

    Stoch %K97.2
    Stoch %D95.5
    Williams %RN/A
    ROC (10d)0.4%
    Momentum0.49
    CCI (20d)141.4
    MFI (14d)80.6

    Volatility Measures

    ATR (14d)$0.37(0.3%)
    StdDev (20d)0.24
    Hist Vol1.4%(Low)

    Volume Flow

    VWAP$135.05
    OBV91.4M
    AD Line-49.1M
    CMF (20d)0.312

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio1.0x
    VWMA (20d)$134.64

    Pivot Points

    R3$135.03
    R2$135.00
    R1$134.99
    Pivot Point$134.96
    S1$134.94
    S2$134.91
    S3$134.90

    Advanced Oscillators

    TSI56.35
    Ultimate Osc66.8
    KST6.10

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$130,000$0$0$0$0$0
    Cost of Revenue$0$0$-400,000$0$0$0N/A$0$0$0N/A$0
    Gross Profit$0$0$400,000$0$0$0$65,000$0$0$0N/A$0
    Operating Expenses$96.00M$82.77M$78.06M$71.28M$73.17M$63.10M$75.88M$58.69M$44.12M$38.18M$37.16M$24.30M
    R&D$67.30M$60.82M$58.44M$54.18M$55.70M$46.39M$60.23M$45.71M$33.21M$28.72M$28.95M$17.07M
    SG&A$24.34M$21.95M$19.61M$17.10M$17.46M$16.71M$15.65M$12.97M$10.92M$9.46M$8.20M$7.24M
    Operating Income$-96,004,000$-82,772,000$-78,056,000$-71,278,000$-73,165,000$-63,096,000$-75,881,000$-58,686,000$-44,122,000$-38,181,000$-37,155,000$-24,305,000
    Interest Income$11.81M$8.74M$8.73M$6.32M$7.14M$7.84M$8.68M$9.67M$10.31M$6.09M$5.42M$3.46M
    Interest Expense$1.58M$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-85,776,000$-74,032,000$-69,325,000$-64,960,000$-66,024,000$-55,256,000$-67,200,000$-49,018,000$-33,816,000$-32,094,000$-31,735,000$-20,840,000
    Income Tax Expense$78,000$79,000$62,000$61,000$72,000$83,000$18,000$0$0$0$0$0
    Net Income$-85,854,000$-74,111,000$-69,387,000$-65,021,000$-66,096,000$-55,339,000$-67,218,000$-49,018,000$-33,816,000$-32,094,000$-31,735,000$-20,840,000
    EBITDA$-97,336,000$-83,913,000$-79,392,000$-72,492,000$-74,526,000$-65,268,000$-78,791,000$-62,143,000$-47,126,000$-40,862,000$-39,994,000$-24,537,000
    EBIT$-96,004,000$-82,772,000$-78,056,000$-71,278,000$-73,165,000$-63,096,000$-75,881,000$-58,686,000$-44,122,000$-38,181,000$-37,155,000$-24,305,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about APGE

    News

    AbbVie completes $8.0 billion notes offering to support Apogee Therapeutics acquisition

    AbbVie Inc. has completed an $8.0 billion senior notes offering to partially fund its acquisition of Apogee Therapeutics, Inc. The offering includes various series of notes with different interest rates and maturity dates, increasing AbbVie's total debt to approximately $78.9 billion. The company also reported strong second-quarter 2026 revenues and raised earnings per share, leading to increased price targets from several analysts.

    Investing.com•8/18/26•
    Neutral

    NINE MASTS CAPITAL Ltd Takes Position in Apogee Therapeutics Inc. $APGE

    NINE MASTS CAPITAL Ltd recently acquired a new position of 9,400 shares in Apogee Therapeutics Inc. (NASDAQ:APGE), valued at approximately $1.25 million. This move comes as institutional investors collectively own 79.04% of the company, despite several analysts downgrading APGE to "hold" or "neutral" with a consensus price target of $124.43. The company also reported a quarterly loss of $1.14 per share, missing estimates, and insiders have sold a significant number of shares recently.

    MarketBeat•8/18/26•
    Neutral

    Apogee Therapeutics CMO Dambkowski sells $737k in stock

    Carl Dambkowski, CMO of Apogee Therapeutics, sold 5,500 shares for $737,934 on August 5, 2026, under a pre-arranged trading plan, while also exercising options to acquire 4,125 shares. This transaction occurred near the stock's 52-week high and after the company's acquisition by AbbVie was approved by shareholders for $10.9 billion. Analysts subsequently downgraded Apogee's stock, though some increased price targets to reflect the acquisition value.

    Investing.com•8/17/26•
    Neutral

    Weekly Recap: $1.3B cash, $85.9M loss and directors resign on AbbVie deal

    Apogee Therapeutics, Inc. (NASDAQ: APGE) reported $1.3 billion in cash but an $85.9 million net loss in Q2 2026, primarily due to increased spending on its zumilokibart program. Its directors are set to resign following the closing of the AbbVie acquisition, which will make Apogee an indirect wholly owned subsidiary of AbbVie.

    TradingView•8/17/26•
    Bearish

    Alberta Investment Management Corp Purchases New Position in Apogee Therapeutics Inc. $APGE

    Alberta Investment Management Corp has acquired a new position in Apogee Therapeutics Inc. (NASDAQ:APGE), purchasing 75,000 shares valued at approximately $9.96 million. Other institutional investors like TD Asset Management Inc., Vanguard Group Inc., and Bank of America Corp DE also increased their stakes in the company. Analysts have issued a consensus "Hold" rating for Apogee Therapeutics, with an average price target of $124.43.

    MarketBeat•8/17/26•
    Neutral

    Frequently Asked Questions About APGE

    Does APGE pay dividends?
    Apogee Therapeutics, Inc. Common Stock (APGE) does not currently pay a regular dividend.
    What is APGE's market cap?
    Apogee Therapeutics, Inc. Common Stock (APGE) has a market capitalization of $10.22B with a current stock price of $135.08.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In